NLBNPIT23EQ3 20240918 18500 (P23EQ3) News

Form 8-K - Current report

Form 8-K - Current report

Lifecore Biomedical Announces Cooperation Agreement with 22NW

CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the...

Form 8-K - Current report

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”...

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM...

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE...

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of...